Le Lézard
Classified in: Health
Subjects: PDT, SCZ, DEI

GammaBoost®, the app defying Alzheimer's


HENDERSON, Nev., May 4, 2021 /PRNewswire/ -- For those who are suffering, GammaBoost® may curb memory loss and combat some of the terrible effects of Alzheimer's. The app is also intended for those at risk or over 50, who are encouraged to use GammaBoost® daily as a preventive measure.

GDI LLC developed the GammaBoost® app in response to numerous published scientific studies, such as those by the National Institute on Aging[1] and the Massachusetts Institute of Technology[2]. These animal studies show that viewing a light that flashes in the "gamma" brainwave frequency range can diminish the beta amyloid plaques associated with Alzheimer's and memory loss.

The innovative GammaBoost® app enables individuals to explore preventive and mitigating effects by providing a 40 flashes per second light source from their smartphone camera's "flash" LED.

The GammaBoost® app is designed for simplicity and ease of use: Touching START flashes the smartphone LED at the gamma rate of 40 flashes per second. After one hour, it turns off automatically and plays a notification sound. Daily one-hour use is suggested. No need to look directly at the LED - the user can just let the flash reflect so that it's visible in their peripheral vision while they work, read, or do other passive tasks.

To allow users to keep track of usage and results, the GammaBoost® app logs dates and minutes of usage.

As a proactive measure, and as potential help for those already suffering, GammaBoost® offers new hope.

In the Apple App Store now. Only $3.99. Coming for Android in May.

1 https://www.nia.nih.gov/news/noninvasive-brain-wave-treatment-reduces-alzheimers-pathology-improves-memory-mice
2 Iaccarino, H.F., et al. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(632):230-235.

This press release was issued through 24-7PressRelease.com. For further information, visit http://www.24-7pressrelease.com.

SOURCE GDI LLC


These press releases may also interest you

at 08:50
Response Pharmaceuticals, Inc., a clinical stage company focused on weight management and metabolic health in high-risk populations, today announced positive topline results from its Phase 1b clinical trial evaluating the safety and efficacy of...

at 08:47
Dr. Mary C. McCluskey, psychotherapist, and author revitalizes Dr. Alfred Adler, the "Pioneer in the Prevention of Mental Health Disorders" and Dr. Pierre Janet "Father of Trauma Treatment Theory" using a time-traveling hot air balloon to create a...

at 08:45
The "Peptide Synthesis: Global Markets 2023-2028" report has been added to ResearchAndMarkets.com's offering. The global market for peptide synthesis is expected to grow from $90.1 billion in 2023 and projected to reach $157.5 billion by the end of...

at 08:45
Ligand Pharmaceuticals Incorporated today announced that it will report first quarter 2024 financial results after the close of the U.S. financial markets on Tuesday, May 7, 2024, and will hold a conference call at 4:30 p.m. Eastern Time that same...

at 08:45
The National Foundation for Infectious Diseases (NFID) and technology company Fraym are partnering on a pilot project to deliver novel, hyperlocal insights to empower public health stakeholders working to increase vaccine uptake across the US....

at 08:44
BioPhotas Inc., manufacturers of the award-winning Celluma SERIES of light therapy devices, recently welcomed Annet King as its new Vice President of Global Sales. Annet has more than 25 years of clinical education and sales management experience and...



News published on and distributed by: